Amicus Therapeutics, Inc. $FOLD Shares Acquired by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC grew its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 271,700 shares of the biopharmaceutical company’s stock after purchasing an additional 23,091 shares during the quarter. Mutual of America Capital Management LLC owned approximately 0.09% of Amicus Therapeutics worth $1,557,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of FOLD. Strs Ohio acquired a new stake in shares of Amicus Therapeutics in the first quarter valued at about $30,000. PNC Financial Services Group Inc. grew its position in shares of Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 3,497 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Amicus Therapeutics in the first quarter valued at about $53,000. CWM LLC grew its position in shares of Amicus Therapeutics by 395.9% in the second quarter. CWM LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 7,502 shares during the period. Finally, 111 Capital acquired a new stake in shares of Amicus Therapeutics in the second quarter valued at about $77,000.

Amicus Therapeutics Price Performance

Shares of FOLD stock opened at $8.67 on Monday. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The firm’s 50-day moving average is $8.02 and its two-hundred day moving average is $6.93. Amicus Therapeutics, Inc. has a 12 month low of $5.51 and a 12 month high of $12.65. The company has a market capitalization of $2.67 billion, a PE ratio of -72.24 and a beta of 0.56.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Wall Street Zen raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday. Needham & Company LLC raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Thursday, September 18th. Morgan Stanley raised shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research note on Thursday, July 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Amicus Therapeutics in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.88.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.